Although the link between osteoprotegerin concentration and cardiovascular risk in patients with CAH has not been evaluated yet, evidence suggests an association between osteoprotegerin and bone metabolism in people with CAH (132, 156, 167). This evidence concerns the gene TNFRSF11B and congenital adrenal hyperplasia.